Sirona Biochem Corp V.SBM

new tweet from SBM

[noclue80]

We are back from the BIO International Convention in San Diego. The interest in our pipeline and the company in general has never been so high!

We have had very in-depth discussions with potential partners, investors and media representatives. We also met with Linda Pullan @PullanConsult and look forward to further cooperation!

More news will follow next week.

Sirona Biochem on Twitter: "We are back from the BIO International Convention in San Diego. The interest in our pipeline and the company in general has never been so high! https://t.co/JIXbls6iTG #partnering #biotech #institutionalinvestors https://t.co/4wEqhrNLoc" / Twitter

[Tickel1st]

This post has been removed in accordance with Community Policy

[noclue80]

agree.. wouldn't be surprised if they would announce to engage Linda in TFC-039 negotiations..

[navajojoe]

This post has been removed in accordance with Community Policy

[Pandora]

Back in December it was announced that the program in China with Wanbang was being dropped because Boehringer had announced a patent issue and the SGLT2 drug was going to be issued as a generic. Or some such words (see below). Anyway it brought the China program for SBM's SGLT2 (TFC-039) to a halt. Have we had a clear update telling us how, where and when this SGLT2 program will get back on

[biorun]

If you look at the most recent presentation updated last week, there may be some answers there. I suspect most didn't bother but it is worth a read.

[Pandora]

There is dialogue there. Not sure I can classify any of it as answers as to how, when and where - but it does talk about it.

[lscfa]

I'm surprized Sirona is keeping Wanbang to manufacture 1067. Maybe, it's temporary until they find another contract manufacturer.   

[PeterG]

Wangbang is not the manufacturer of 1067.

[bazooka73]

but they are for TFC-039

[Pandora]

Did you read this or did you not read this: This year, Empagliflozin (developed by Boehringer Ingelheim and Eli Lilly) failed to uphold patent protection in China, which created a generic environment for SGLT2 inhibitors. It was reported to us TFC-039 performed well in the clinical trials, however, given the generic situation, it did not make good business sense for Wanbang to continue a lengthy

[bazooka73]

Did you read this?   "We are pleased to inform our shareholders that Sirona and Wanbang have signed a binding Letter of Intent (LOI) to collaborate on licencing efforts for Sirona’s SGLT2 inhibitor, TFC-039, as a treatment for diabetes in animal health. We have a long-standing relationship with Wanbang and are excited to combine our two companies’ expertise to license TFC-039 to a

[Pandora]

What is the date on your document? Mine was written on December 13, 2021 and it seems to say the Wanbang work was being ceased because of the drug going generic. "however, given the generic situation, it did not make good business sense for Wanbang to continue a lengthy and costly development”, said Dr. Howard Verrico, CEO of Sirona Biochem." Do you have something after December 13

[bazooka73]

CEO Quarterly Update 2021

[bazooka73]

of course 2022!

[Pandora]

I stand corrected. Don't think I found the April update when looking at the site. Oh well, I guess they still have something going but remains to be seen how effective it might be.

[MirrorWorldMan]

It is difficult to understand why Howie wants to still to business with Wannabang,  Afterall, it took 10 years to do anything with our SGLT2 and then that company dumped us for generics.  They must of know of the pending favourable generic government policies and strung us along.  Now they are saying we go to pets.  Whats stopping anyone from using a generic SGLT2 in pets as

[Pandora]

From that April update: "The combined scientific knowledge of Sirona and Wanbang will significantly increase the speed to commercialization of TFC-039. This includes extensive data, advanced manufacturing process development and the ability to commercially manufacture TFC-039. The new agreement was a desired step on the part of the interested partners to create the legal framework and to

[MirrorWorldMan]

Agents within tyhe SGLT2 class already have an abundance of indications and I don't see what a new indication with a unproven SGLT2 like our own can add to that. The existing SGLT2's have Cardio/Renal/Renal/Weight Loss indications etc beyond their initial Diabetes indications, plus millions of patients of with real world experience.  Now, the best of them, Empa, is genericized in

[JLangi9]

Either sell your shares or stfu... you are continuously trying to bring this stock down with your own two hands, face the fact that this stock is trending up and please just do us the favour of keeping quiet - half the stuff you type is hard enough to read grammatically, not to mention negative. You have the option to get out with a profit... or are you one of the few trying to short? Speak up

[Tickel1st]

This post has been removed in accordance with Community Policy

[Pandora]

  Nugen Medical releases needle-free injection for pets   2022-06-22 11:39 ET - News Release   Mr. Michael Wright reports NUGEN M.D. LAUNCHES PETJET(TM) PROVIDING NEEDLE-FREE INJECTIONS FOR DOMESTICATED PETS Nugen Medical Devices Inc. will be launching a needle-free injection device specifically designed for domesticated household pets. The PetJetTM will allow pet

[biorun]

their investors didn't like that announcement- the are down 31% 

[Pandora]

Yes, definitely a good example of "sell on news". Not sure what it means but this is a post from the NGMD board: NUGEN stock manipulation Great company but stay wise when you see Broker 1 on any small cap. Brutal stock manipulaiton with electronic trading. Have seen with high sell put in to stop Stock price rise at last minute before bell and then gone off screen at last